Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03853317 · ClinicalTrials.gov registry record · Phase 2
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
A Phase 2 study, sponsored by ImmunityBio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT03853317 is a Phase 2 study that was terminated before completion, run by ImmunityBio. The registered enrollment target is 9 participants.
The verdict
NCT03853317, a Phase 2 study, was terminated before completion, sponsored by ImmunityBio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
Phase 2, single-arm study to evaluate combination therapy of avelumab, haNK and N-803 in patients with Merkel Cell Carcinoma who have progressed on or after checkpoint inhibitor therapy as assessed by ORR. Patients will receive treatment for a maximum of two years.
Interventions
- BIOLOGICAL Avelumab
- BIOLOGICAL N-803
- BIOLOGICAL haNK™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-02-19 |
| Est. Completion | 2022-09-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03853317
The ClinicalTrials.gov registry entry for NCT03853317 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Avelumab is the first listed.
NCT03853317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03853317 about?
NCT03853317 is a clinical study titled "QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy". Phase 2, single-arm study to evaluate combination therapy of avelumab, haNK and N-803 in patients with Merkel Cell Carcinoma who have progressed on or after checkpoint inhibitor therapy as assessed by ORR. Patients will receive treatment for a maximum of two years.
What is the current status of trial NCT03853317?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2020-02-19. Estimated completion is 2022-09-19.
What interventions are being tested in trial NCT03853317?
The interventions under investigation include: Avelumab (BIOLOGICAL), N-803 (BIOLOGICAL), haNK™ (BIOLOGICAL).
Who is sponsoring clinical trial NCT03853317?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.